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às tomadas de decisão em saúde. Desenvolvimento: A Lógica Paraconsistente é 
uma opção metodológica que permite manipular dados imprecisos, inconsitentes 
e paracompletos. A aplicação do método consiste basicamente de oito etapas: 
1-fixar o nível de exigência da decisão que se pretende tomar; 2-selecionar os 
fatores mais importantes e de maior influência na decisão; 3-estabelecer as seções 
para cada um dos fatores; 4-construir a base de dados que é constituída pelos 
pesos atribuídos aos fatores e pelos valores de evidência favorável e de evidência 
contrária atribuídos a cada um dos fatores em cada uma das seções (os pesos e 
os valores das evidências são atribuídos por especialistas selecionados para o 
estudo); 5-fazer a pesquisa de campo para verificar, no caso em análise, em que 
seção (condição) cada um dos fatores se encontra; 6-obter o valor da evidência 
favorável e o valor da evidência contrária resultantes para cada um dos fatores 
escolhidos, por meio da aplicação das técnicas de maximização e minimização 
da LPAE; 7- obter o grau de evidência favorável e o grau de evidência contrária 
do baricentro dos pontos que representam os fatores escolhidos no reticulado 
paraconsistente; 8-tomar a decisão, aplicando-se a regra de decisão ou algoritmo 
para-analisador. ConClusão: Em situações em que a tomada de decisão precisa 
ser realizada em curto período de tempo, transferir e adaptar avaliações econômi-
cas realizadas em outros contextos pode ser uma necessidade considerável. O 
método paraconsistente pode contribuir nesse processo, apoiando o trabalho das 
comissões hospitalares de avaliação e incorporação de tecnologias em saúde.
DISEASE – SPECIFIC STUDIES
CANCER – Clinical Outcomes Studies
PCN1
PhARmACOvIgIlANCE IN ONCOlOgy: KNOwlEDgE AND PERCEPTION ON 
ADvERSE EvENTS REPORTINg IN BRAzIl
Holtz L1, Cecilio L1, Minowa E2, Julian G3
1Oncoguia, São Paulo, Brazil, 2Evidências - Kantar Health, Campinas, Brazil, 3Evidências - Kantar 
Health, São Paulo, Brazil
objeCtives: Pharmacovigilance represents an important tool to support the 
maintenance of drug safety through evaluation of spontaneous adverse events (AE) 
reporting. AEs represent one important cause of morbidity and mortality world-
wide when not managed correctly, being very frequent, especially during oncology 
treatments. However, underreported phenomenon occurs often due inefficient 
spontaneous reporting by patients, physicians and caregivers. Therefore, the aim 
of this survey was to evaluate the knowledge and perception related to pharma-
covigilance in Brazil. methoDs: From February to March 2015, 260 respondents 
answered an internet-based survey related to knowledge on pharmacovigilance 
from Oncoguia Institute, an independent nonprofit cancer advocacy institution. 
Descriptive analyses were performed according to answers frequency. Results: 
Among the respondents, 70.8% were diagnosed with cancer, of which breast cancer 
was the most frequent (58%) followed by colorectal cancer (4%). Reported treat-
ment included chemotherapy (96%), surgery (84%), 48% radiotherapy (48%). Of all, 
46% and 44% were treated by public and private health insurance, respectively. 
Most of the respondents were not aware of the importance of a pharmacovigi-
lance AE report (52%). In fact, 21% of the respondents were not aware of what AEs 
are. In 66% of the cases, physicians have described the main AE expected to the 
prescribed treatment. Respondents reported nausea (80%), hair loss (77%), weight 
gain (49%) and vomiting (45%) as the most common AEs. Only 7% and 4% of the 
respondents were aware that AEs could be reported to pharmaceutical industry 
and ANVISA, respectively. ConClusions: This survey demonstrates that knowl-
edge and perception regarding AEs, such as definition, importance and how to 
proceed in case of having one, including the importance of pharmacovigilance 
system, are very reduced among common public, including cancer patients. 
Therefore, there is an enormous need for educational intervention regarding AEs 
reporting importance in general public, patients and physicians, especially in 
oncology.
PCN2
EFICACIA y SEgURIDAD DEl USO DEl CETUxImAB EN PACIENTES CON CANCER 
COlORRECTAl mETASTáSICO
Croci A1, Aleman A2, Perez Galan A2
1Ministry of Public Health, montevideo, Uruguay, 2Ministry of Public Health, Montevideo, Uruguay
objeCtivos: Determinar la eficacia y seguridad de Cetuximab solo o asociado a 
otros fármacos en el tratamiento del cáncer colo-rectal metastásico comparado a los 
tratamientos actualmente disponibles metoDologíAs: Se realizó una búsqueda 
bibliográfica de revisiones sistemáticas y Ensayos Clínicos Aleatorizados (ECAS) en 
bases electrónicas Cochrane, Pubmed y Lilacs, que compararan ramas de tratami-
ento con y sin Cetuximab ResultADos: Se seleccionaron 2 revisiones sistemáti-
cas y 8 ECAS. Los resultados para los puntos finales de eficacia y seguridad en la 
población general fueron: Sobrevida Global (SG) HR 0,97 [0,89-1,05], Sobrevida Libre 
de Progresión (SLP) HR 0,84 [0,70-0,98], eventos adversos (EA) grado 3-4 HR 2,15 [1,88-
2,45] y reacciones de piel 44,5 [22,1-89,5]. En la población KRAS wild la SG fue HR 
0,796 IC95% [0,670-0,946] en el estudio de Van Cutsem, HR, 0,855 IC95% [0,599-1,219] 
en el estudio de Bokemeyer, 1,04 IC95% [0,87-1,23] en el estudio de Maughan y HR 
0,55 IC95% [0,41-0,74] en el estudio de Jonker. Para la SLP en población KRAS wild 
los resultados fueron HR 0,57 IC95% [0,38-0,86] en el estudio de Bokemeyer, HR 0,40 
IC95% [0,30-0,53] en el estudio de Jonker, HR 0,96 IC96% [0,82-1,12] en el estudio de 
Maughan y HR 0,70 IC95% [0,56-0,87] en el estudio de Van Cutsem ConClusiones: 
Los resultados analizados muestran un incremento en la SG en pacientes con KRAS 
wild y de la SLP. También se constata un incremento en la ocurrencia de EA graves. 
Considerando los resultados de eficacia y seguridad para Cetuximab, se recomienda 
realizar un estudio de costo-efectividad para decidir su posible inclusión en el FTM. 
En este sentido, no debe darse por concluida la evaluación hasta contar con dicha 
información.
bonded to SV by hydrophobic interactions, while OH groups are oriented towards 
the outer side of the aggregate. Hence, the formed aggregate is more hydrophilic 
than SV molecule alone. ConClusions: Our data indicate that CA decreases the 
values of SV distribution coefficient. This may be the result of the formation of 
hydrophilic complexes increasing the solubility of SV that could consequently lead 
to the increase of SV bioavailability. In order to confirm these results, further in 
vivo investigations of their interactions at molecular level need to be undertaken. 
Acknowledgement: This work is supported by Ministry of Education, Science and 
Technological Development of Serbia, Project III41012.
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COmPARISON OF ChRONIC hEPATITIS C TREATmENT EFFICACy IN 
RANDOmIzED CONTROllED TRIAlS AND REAl-lIFE STUDIES - INFlUENCE OF 
STUDy DESIgN IN ThE SUSTAINED vIROlOgICAl RESPONSE: A SySTEmATIC 
REvIEw OF PUBlIShED lITERATURE
Vaisberg VV, Kim V, Ono SK, Mendes LC, Carrilho FJ
University of São Paulo School of Medicine, São Paulo, Brazil
objeCtives: To assess whether hepatitis C treatment outcome was similar among 
different study designs. methoDs: Two independent reviewers conducted a 
double-screened systematic review on hepatitis C treatment. Studies were cat-
egorized under study design: randomized controled trials (RCT), pragmatic trials 
(PRG) and registries; and treatment course: pegylated interferon and ribavirin (IR), 
IR and boceprevir (BCP), IR and telaprevir (TLP). 3,713 abstracts were retrieved, 
and 253 studies were included according to previously selected criteria, compris-
ing 77,042 patients. Sustained virological response (SVR) was stablished as treat-
ment end-point. Mann-Whitney-U and Kruskall-Wallis tests were used with a 95% 
CI. Results: In the IR group, registries had a lower SVR than PRG (P= 0.039) and than 
RCT (P= 0,3368). RCT had a worse outcome than PRG (P= 0.283). Statistical difference 
was seen among the three BCP groups (P= 0.040), and RCT had a higher SVR than 
registries (P= 0.028). BCP PRG group couldn’t be analysed in comparison to other 
study designs due to a very small group. PRG (SVR= 80.13%) had a better outcome 
than RCT (SVR= 75.00%) and than registries (SVR= 62.00%), but tests have shown 
no statistical significance among study designs (P> 0.05). ConClusions: It’s pos-
sible to design close to the real-life settings RCT. Though it’s not a rule, each drug 
should be studied separately and its clinical scenario considered. PRG might be not 
as pragmatic as they claim to be, as their results were more similar to RCT than to 
registries. Further analysis should assess whether PRG are fully bridging RCT’s gap to 
the real-life settings, as they are intent to be the main guide to drug’s embodiment to 
the clinical practice. Also, boceprevir was less studied than telaprevir, and whether 
remains unclear which drug is more effective, new data could answer that, specially 
a large proportions head-to-head RCT comparing both drugs. Although, as of new 
and better treatment courses are approved, this RCT most probably will not be done.
RESEARCh ON mEThODS – Conceptual Papers
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ENgAgINg hISPANIC CAREgIvERS IN RESEARCh: A FRAmEwORK TO DESIgN 
CUlTURAlly SENSITIvE APPROAChES FOR ENgAgEmENT IN  
PATIENT-CENTERED OUTCOmES RESEARCh
Camelo Castillo W1, Hendricks J2, dosReis S3
1University of Maryland School of Pharmacy School of Pharmacy, Baltimore, MD, USA, 2Maryland 
Coalition fo Families for Children’s Mental Health, Hagerstown, MD, USA, 3University of Maryland 
School of Pharmacy, Baltimore, MD, USA
The Latin American perspective on caregivers’ preferences is underrepresented in 
research largely due to lack of culturally sensitive approaches to enhance research 
literacy. Identification of the most effective engagement strategies is needed so 
that patient centered outcomes research (PCOR) can address the needs and pri-
orities of caregivers of Latin American origin. Our objectives were to develop a 
methodological framework for engaging caregivers of Latin American origin in 
research and to improve PCOR literacy in this population. The ‘pre-engagement’ 
framework with hard-to-reach patients was used in a study designed to identify 
caregivers’ priorities for treatment and outcomes in children of Hispanic origin 
living in the U.S. with complex mental health conditions. Based on the principles 
of community based participatory research, the pre-engagement implementa-
tion phases were: 1. Identify Hispanic community leaders with common goals; 2. 
Partner with leaders to select key topics of interest; 3. Design culturally appropriate 
strategies; 4. Implement pre-engagement strategies. During phase 1, academic 
partnerships were developed with community leaders to allow integration into the 
research process. Community needs and practical challenges to engage caregivers 
and the strategies to overcome barriers were identified during phase 2. In phase 
3, a series of four workshops, delivered in Spanish, were designed as interac-
tive activities each addressing a unique challenge: understanding the caregiver’s 
perspective, understanding the child’s perspective, providing behavior manage-
ment strategies, and discussing community resources for families. Each workshop 
emphasized research literacy by linking the benefit of research in advancing the 
challenge being discussed. An outcome of this work will be a caregiver resource 
guide in Spanish, developed by Hispanic community leaders, for distribution in 
their communities. In the absence of culturally appropriate tools to address health 
and medical preferences of non-English speaking communities, this framework 
can be used to engage caregivers and communities in patient-centered research.
PRm19
O méTODO PARACONSISTENTE COmO SUPORTE ÀS TOmADAS DE DECISãO Em 
SAúDE
Campolina AG, Costa A, López RV
Cancer Institute of the State of São Paulo, Sao Paulo, Brazil
intRoDução: O presente estudo objetiva apresentar a Lógica Paraconsistente 
Anotada Evidencial (LPAE), que é a base teórica para o modelo proposto de suporte 
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TRASTUzUmAB EmTANSINE FOR hER2 POSITIvE BREAST CANCER PATIENTS: 
AN UPDATED SySTEmATIC REvIEw
Valle PM1, Mosegui GB1, Vianna CM2, Araújo RL3, Felicissimo T3, Lima IJ4
1Universidade Federal Fluminense, Niterói, Brazil, 2UERJ, Rio de Janeiro, Rio de Janeiro, Brazil, 
3Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 4Universidade Federal de Itajubá, 
Itajubá, Brazil
objeCtives: Trastuzumab emtansine is a drug used in patients affected by meta-
static breast cancer HER-2 positive that did not respond to available treatments. The 
administration of this drug can provide a substantial impact on reducing the need to 
perform mastectomies as well as increasing the life expectancy of a high number of 
patients, once breast cancer is associated to high mortality and incidence rates. The 
main objective of this study is to collect evidences of efficacy and safety of this treat-
ment option. methoDs: Evidences were found determining key terms to research 
strategy and its utilization in databases. Inclusion criteria were defined according 
to the PICO question developed and included clinical trials, observational studies, 
systematic reviews and meta-analyses. No filters were utilized to publication year 
or study language. No exclusion criteria were performed. Results: The research 
collected evidences from 7 clinical trials, 1 observational study, 1 systematic review 
and none meta-analysis. Randomized trials compared trastuzumab emtansine with 
lapatinib and capecitabine in combination or physician’s choice. Main efficacy out-
comes observed in these studies were progression free-survival, overall survival, 
response rates (complete, partial and/or objective) and time until disease progres-
sion, which were improved by trastuzumab emtansine in comparison with other 
treatment options. According to safety evaluations, it was observed that patients 
treated with trastuzumab emtansine had lower severity and frequency of adverse 
events than patients who received other option in addition to present a favorable 
cardiotoxicity profile. ConClusions: Due to the results observed in the collected 
studies, trastuzumab emtansine provided a higher life expectancy to the enrolled 
patients and was well tolerated. In comparison to available treatments, this drug 
caused less severity adverse events in most of cases. Trastuzumab emtansine was 
more effective in HER2 positive breast cancer than patients with negative disease 
to this protein.
PCN7
UTIlIzAçãO DO ESCORE DE PROPENSãO NA COmPARAçãO DE DUAS OPç’ES 
TERAPêUTICAS Em PACIENTES COm CARCINOmA EPIDERm”IDE DE CABEçA E 
PESCOçO, BRASIl 1998-2008
Campolina AG, Costa A, López RV
Cancer Institute of the State of São Paulo, Sao Paulo, Brazil
objetivos: Comparar o efeito de duas modalidades terapêuticas (cirurgia e radi-
oterapia) na sobrevida de pacientes com câncer de cabeça e pescoço (CCP) utili-
zando ométodo de pareamento pelo escore de propensão. métoDos: Coorte com 
561 pacientes com CCP, participantes de um estudo multicêntrico em oito centros 
clínicos do Brasil (1998 a 2008),foram incluídos na análise. O cálculo dos escores 
de propensão foi realizado pela regressão logística considerando as variáveis de 
confundimento: gênero, idade no diagnóstico, nível de escolaridade, consumo de 
tabaco e álcool, estadiamento clínico e localização do tumor.O desfecho princi-
pal foi o óbito, e foram calculadas as razoes de chances (RC) e seus respectivos 
intervalos de confiança de 95% (IC95%) segundo o modelo de regressão logística 
não condicional e condicional univariável e múltipla. ResultADos: Os valores do 
escore de propensão variaram de 0,0524 a 0,7275.no modelo convencional ajustado 
pelas variáveis de confusão o valor da RC para a radioterapia foi de 6,68 (IC95% 4,1-
10,9; p< 0,001). Quando utilizado o escore de propensão como variável de ajuste, 
os pacientes que receberam radioterapia tiveram RC de 6,9 comparado com aque-
les que fizeram cirurgia (IC95% 4,5-10,5; p< 0,001). Após o pareamento pelo escore 
de propensão, 195 pares foram formados, e pacientes que receberam radioterapia 
tiveram uma RC de 12,8 comparado com pacientes que fizeram cirurgia (IC95% 
4,5-37; p< 0,001). ConClusões: Observamos um efeito maior do tratamento cirúr-
gico antes e após a utilização do ajuste pelo escore de propensão, ou seja, menor 
risco de morte. Os critérios para a construção do escore de propensão precisam de 
conhecimento das variáveis relacionadas com o desfecho e o tratamento, e não 
necessariamente obedecem a critérios estatísticos.
PCN8
EFICACIA DE DOCETAxEl EN PACIENTES CON CáNCER DE PROSTATA 
RESISTENTE A CASTRACI”N EN PRImERA líNEA DE TRATAmIENTO
Villa JC, Espinosa J, Gomez R, Sanchez V, Lopez R, Galan R, Pineda MD, Perez M
CIUDAD REAL UNIVERSITY GENERAL HOSPITAL, CIUDAD REAL, Spain
objeCtivos: El cáncer de próstata es el primer tumor en incidencia en el varón. El 
tratamiento de primera línea del cáncer de próstata resistente a castración (CPRC) 
incluye el docetaxel, enzalutamida y la abiraterona. La supervivencia global (OS) del 
CPRC actualmente alcanza los 30. Tras la publicación del estudio CHAARTED el posi-
cionamiento de docetaxel se sitúa en primer lugar. El objetivo primario es comparar 
nuestros datos de supervivencia de los pacientes diagnosticados de CPRC tratados 
con docetaxel. metoDologíAs: Desde enero de 2010, se han reclutado un total 
de 67 pacientes en seguimiento en Consulta de Oncología Médica diagnosticados 
de CPRC tratados con docetaxel. Se han analizado las características clínicas del 
paciente, el estado sintomático/asintomático en el momento de la primera visita, 
el PSA, el gleason y las localizaciones metastásicas. El análisis de la superviven-
cia global se ha hecho según el método Kaplan Meier (log rank). ResultADos: 
La mediana de edad fue de 71 años, el 61% presentaba un gleason indiferenciado 
al diagnóstico y la localización metastásica más frecuente fue la ósea (90,9%). La 
mediana de PSA fue de 58,2 ng/mL. El 70% de los pacientes estaban sintomáticos 
siendo el dolor el síntoma más frecuente (74,4%). El 81% de los pacientes obtienen 
beneficio clínico tras el primer mes de tratamiento. La supervivencia global obtenida 
ha sido de 28,1 meses. Haciendo un análisis por subgrupos, el estado asintomático al 
inicio de la quimioterapia con docetaxel supone una mejor supervivencia (p= 0,000). 
Por el contrario, el PSA al inicio de la quimioterapia no implican un impacto en la 
PCN3
hEmATOlOgICAl TOxICITIES ASSOCIATED wITh PAzOPANIB USE IN CANCER 
PATIENTS: A mETA-ANAlySIS
Saiyed MM1, Shah C2
1National University of Singapore, Singapore, Singapore, 2S.J.M college of pharmacy, Chitradurga, 
India
objeCtives: To perform an up-to-date meta-analysis of trials to evaluate the 
risk of pazopanib-related hematologic toxicities. methoDs: Several databases 
were searched including PubMed, Scopus, Web of Science, trial registries and 
Cochrane databases. Eligible studies were phase II and III prospective clinical trials 
of patients with cancer assigned drug pazopanib 800 mg/day with data on hema-
tologic toxicities. Overall incidence rates, relative risk (RR), and 95 % confidence 
intervals (CI) were calculated employing fixed or random effects models depend-
ing on the heterogeneity of the included trials. Results: A total of 3972 patients 
were included from 17 clinical trials. The incidences of pazopanib-associated 
all-grade anemia, neutropenia, thrombocytopenia and lymphopenia were 30.5%, 
26.9%, 20.6% and 32.8%, respectively. The incidences of high-grade events were 
3.9%, 4.0%, 2.8% and 5.8%, respectively. Pazopanib is associated with significant 
risk of all-grade (RR = 4.20, 95% CI, 3.16 – 5.56) and high-grade (RR = 6.12, 95% CI, 
3.07 – 12.23) neutropenia, all-grade (RR = 6.27, 95%, CI, 4.10 – 9.57) and high-grade 
(RR = 3.59, 95% CI, 1.30 -9.91) thrombocytopenia. ConClusions: This is the first 
meta-analysis to demonstrate a significantly increased risk of all-grade and high-
grade neutropenia and thrombocytopenia with pazopanib compared with control. 
Clinicians should be aware of this risk and provide close monitoring in patients 
receiving these therapies.
PCN4
COmPARAçãO DE TRATAmENTOS PARA CâNCER DE CABEçA E PESCOçO 
AjUSTADO POR ESCORE DE PROPENSãO: RADIOTERAPIA vERSUS 
CIRURgIA+RADIOTERAPIA
Campolina AG1, Costa A1, Leandro RF2, López RV1, Soarez PC2
1Cancer Institute of the State of São Paulo, Sao Paulo, Brazil, 2Sao Paulo University, São Paulo, 
Brazil
objetivos: Avaliar a sobrevida dos pacientes com câncer de cabeça e pescoço 
(CCP) avançado (estadiamento clínico III e IV) que receberam tratamento com 
radioterapia ou cirurgia+radioterapia, através do método de estratificação pelo 
escore de propensão (EP). métoDos: Participaram 391 pacientes de uma coorte 
com CCP avançado (III e IV), recrutados para um estudo multicêntrico brasileiro 
(1998 e 2008). O EP foi calculado por meio de regressão logística para as seguintes 
variáveis de confundimento: idade, sexo, escolaridade, tabagismo, alcoolismo e 
localização do tumor. O desfecho avaliado foi óbito com cálculo dos riscos relativos 
(RR) e intervalo de confiança de 95% (IC95%), conforme o modelo de regressão de 
Cox univariável e múltipla. ResultADos: Os EP’s variaram de 0,3145 a 0,8901. Com 
a utilização do modelo de regressão de Cox ajustado pelas variáveis de confusão 
o RR para cirurgia+radioterapia foi de 0,343 (IC95% 0,260-0,452; p< 0,001). Após 
a estratificação pelo EP para tercil, 3 grupos foram formados com 129 pacientes 
no primeiro e segundo tercis e 28 pacientes no terceiro. Na regressão de Cox 
foram obtidos os seguintes ResultADos: primeiro tercil RR= 28,64 (IC95%; 
p< 0,001), segundo RR= 19,77(IC95%; p< 0,001) e o terceiro RR= 17,75 (IC95%; 
p< 0,001). A utilização do EP estratificado por tercil obteve RR= 0,32 (IC95% 0,20-
0,51; p< 0,001) com um risco de morrer de 0,729 para o tratamento radioterapia; 
o segundo tercil com RR= 0,37 (IC95% 0,23-0,60; p< 0,001) apresenta risco de mor-
rer de 0,63 para radioterapia; e o terceiro 0,27 (IC95% 0,15-0,49; p< 0,001) com 
risco de morrer 0,73. ConClusões: A abordagem cirurgia+radioterapia apre-
sentou maior efetividade nos dois métodos de avaliação, indicando um menor 
risco de morrer por esse tratamento. O EP permitiu aumentar a precisão e reduzir 
os vieses de seleção na comparação da efetividade terapêutica em estudos 
observacionais.
PCN5
OPTImIzACION DE lA QUImIOTERAPIA EN El CáNCER EPIDERmOIDE DE 
PUlmON AvANzADO, ANTImETABOlITOS O TAxANOS?
Espinosa J, Villa JC, Gomez R, Sanchez V, Lopez R, Galan R, Cano JM, Murcia M
CIUDAD REAL UNIVERSITY GENERAL HOSPITAL, CIUDAD REAL, Spain
objeCtivos: El subtipo escamoso de cáncer de pulmon no microcítico (CPNM) 
constituye el 45% de todos los CPNM. El tratamiento de primera línea debe incluir 
cisplatino o carboplatino y un fármaco de tercera generación (taxanos, alcaloides 
de la vinca y antimetabolitos). No existe ningún estudio de fase III que analice cual 
es el doblete más activo en el CPNM subtipo escamoso. Nuestro estudio pretende 
dilucidar esta cuestión investigando como influyen en la supervivencia global 
(OS). metoDologíAs: Desde enero de 2012 hasta la fecha actual, se han reclutado 
82 casos de CPNM avanzado con histología escamosa. Se han tenido en cuenta 
las características clínicas, la presencia de metástasis cerebrales al diagnóstico, el 
empleo de antimetabolitos o inhibidores de microtúbulos. El análisis de OS se ha 
hecho según el método Kaplan Meier (log rank) y el análisis multivariado incluy-
endo la edad, el sexo y la presencia de metástasis cerebrales según el modelo de 
Cox. ResultADos: La mediana de edad fue de 70 años (50% mayores de 70 años), 
el 3,7% eran mujeres y el 2,4% presentaron metástasis cerebrales. La supervivencia 
global obtenida 8,246 meses CI95% [5,8–2,6]. Por subgrupos, el hombre presenta una 
OS de 8,3 meses frente a 3,2 de la mujer (P= 0,006, HR= 0,2) y los pacientes tratados 
con antimetabolitos 9,45 meses versus 5,7 meses en los tratados con inhibidores 
de los microtúbulos (p= 0,018; HR= 1,98). El uso de carboplatino o cisplatino o la 
presencia de metástasis cerebrales no implican un impacto en la supervivencia 
(p= 0,26 y 0,59). En el análisis multivariado el género y el tipo de quimioterapia 
empleada son significativos (p= 0,09 y 0,018 respectivamente). ConClusiones: El 
tratamiento de los pacientes con CPNM variedad escamosa debe incluir antime-
tabolitos en la primera línea independientemente del tipo de platino empleado. El 
género femenino implica un peor pronóstico. Se necesitan estudios clínicos que 
confirmen estos datos
